Advertisement

Topics

Week in Review: Tasly Biopharma Completes Pre-IPO Round at $1.9 Billion Valuation

22:03 EDT 14 Jul 2018 | ChinaBio Today

Deals and Financings

  • Tasly Biopharma of Shanghai raised $84.5 million in new capital and paid $48 million in stock to buy out China JV partner Transgene in a pre-IPO round that values Tasly at $1.9 billion; the company plans to IPO in Hong Kong;
  • GT Healthcare Capital of China and Sonder Capital of Silicon Valley closed a $26.6 million round in San Francico's Potero Medical, a medical device company;
  • Beijing's Hillhouse Capital and Sirona Capital of Australia co-led a $15 million Series C-1 funding for Antiva Bioscience, a South San Francisco biopharma;
  • CC-Pharming of Beijing paid $4.7 million to in-license use of a plant-based technology developed by Texas' iBio to develop and manufacture antibodies;
  • Adlai Nortye Biopharma, a Hangzhou oncology in-licensing company, acquired global rights to a clinical-stage Novartis cancer drug, buparlisib;
  • Haitong International of Hong Kong led the first close of a Series B round in Orig3n, a Boston genetics and regenerative medicine company;
  • Germany's Merck KGaA will market Xian Janssen's Inovokana®, a SGLT-2 treatment for type 2 diabetes, in China;
  • Zhejiang Dian Diagnostics formed a partnership with San Diego's Agena Biosciences to promote Agena's MassARRAY® System in China;
  • IDS Medical Systems of Hong Kong partnered with WeDoctor, the Tencent online healthcare portal, to provide an online supply of medical devices;

Trials and Approvals

  • Suzhou CStone Pharma was approved to start China trials of its PD-1 mAb, after a short, four-month review period;
  • Adagene of Suzhou was approved to begin US trials of its lead product, ADG-106, in patients with advanced solid tumors and non-Hodgkin lymphoma.

Stock Symbols: (SHA: 600535) (SHA: 600535) (P: TNG) (NYSE AMERICAN:IBIO) (NYSE: NVS) (F: MRK) (HK: 0700)

Share this with colleagues:

Original Article: Week in Review: Tasly Biopharma Completes Pre-IPO Round at $1.9 Billion Valuation

NEXT ARTICLE

More From BioPortfolio on "Week in Review: Tasly Biopharma Completes Pre-IPO Round at $1.9 Billion Valuation"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Healthcare
Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...